Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinmajiedu Granules is a Traditional Chinese Medicine (TCM) compound preparation developed by the First Affiliated Hospital of Zhengzhou University. It is primarily indicated for the treatment of acute respiratory distress syndrome (ARDS), particularly in cases associated with severe viral pneumonia such as COVID-19. The formulation is designed to clear heat, detoxify, and resolve phlegm, aiming to mitigate the systemic inflammatory response syndrome (SIRS) and the associated cytokine storm. By modulating immune activity and reducing the levels of pro-inflammatory mediators like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), the granules work to improve pulmonary function and enhance oxygenation indices in critically ill patients. The preparation typically consists of several herbal extracts, including *Lonicera japonica* and *Ephedra sinica*, which provide anti-inflammatory and immunomodulatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinmajiedu Granules.